By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Wealth Beat NewsWealth Beat News
  • Home
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Notification Show More
Aa
Wealth Beat NewsWealth Beat News
Aa
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Follow US
Wealth Beat News > News > XSVM: Reasons Why I’m Not Upgrading This Value & Momentum Vehicle
News

XSVM: Reasons Why I’m Not Upgrading This Value & Momentum Vehicle

News
Last updated: 2023/11/10 at 10:35 AM
By News
Share
12 Min Read
SHARE

Contents
Bulls have a lot to sayRobust performance since the index changePhenomenal value factor exposureBears are retortingBe prepared for excruciating volatilityHigh turnover is to be toleratedNumerous EPS contraction storiesQuality: expectations should not be set too highFinal thoughts

It has been close to two years since I presented a mostly skeptical analysis of the Invesco S&P SmallCap Value with Momentum ETF (NYSEARCA:XSVM), a fund with a strategy built around a combination of seemingly contradictory concepts of underappreciated equities and robust price performance.

According to the Invesco website, the basis for XSVM’s passive strategy is the S&P 600 High Momentum Value Index. The benchmark encompasses 120 constituents of the S&P 600, a well-known small-cap echelon barometer, selected using value and momentum scores, with the most undervalued names receiving greater weights. According to the prospectus, the following metrics are used:

In selecting constituent securities for the Underlying Index, the Index Provider first calculates the value score of each stock in the Parent Index by evaluating each stock’s: (i) book value-to-price ratio, calculated using the company’s latest book value per share divided by its price; (ii) earnings-to-price ratio, calculated using the company’s3 trailing 12-month earnings per share divided by its price; and (iii) sales-to-price ratio, calculated using the company’s trailing 12-month sales per share divided by its price…

The Index Provider calculates a security’s momentum score by evaluating the percentage change in the stock’s price over the last 12 months, excluding the most recent month, and applying an adjustment based on the security’s volatility over that period.

Reconstitution and rebalancing follow a semi-annual schedule (June and December).

Today’s note is supposed to provide a balanced overview of the ETF, as an update has been long overdue. More specifically, I would like to not only present a few bullish arguments that optimists might leverage in their buy theses on the vehicle but also counter them with some bearish facts that, at the end of the day, persuaded me not to upgrade the rating.

Bulls have a lot to say

Robust performance since the index change

A note of caution is that despite XSVM’s returns tracing back to its inception in March 2005, they are of no use for the most part as the fund changed its underlying index in June 2019. In this regard, I would like to pay attention only to the July 2019-October 2023 period.

So, the performance story the fund has delivered is nothing short of robust. Below is the total return it clocked, as well as a few other relevant metrics, compared to the results of the iShares Core S&P 500 ETF (IVV) and iShares Core S&P Small-Cap ETF (IJR). I also decided to add its peers targeting mid-cap and mega/large-cap echelons, namely the Invesco S&P 500Value with Momentum ETF (SPVM) and Invesco S&P MidCapValue with Momentum ETF (XMVM).

Portfolio XSVM IVV IJR XMVM SPVM
Initial Balance $10,000 $10,000 $10,000 $10,000 $10,000
Final Balance $16,492 $15,307 $12,126 $14,069 $12,644
CAGR 12.24% 10.32% 4.55% 8.20% 5.56%
Stdev 30.65% 18.55% 23.84% 25.92% 22.41%
Best Year 55.89% 28.76% 26.60% 34.72% 28.40%
Worst Year -13.64% -18.16% -16.19% -8.23% -4.14%
Max. Drawdown -40.97% -23.93% -32.77% -35.24% -34.22%
Sharpe Ratio 0.48 0.53 0.23 0.37 0.28
Sortino Ratio 0.73 0.81 0.34 0.54 0.38
Market Correlation 0.8 1 0.9 0.88 0.87

Data from Portfolio Visualizer

Neither the market proxied with IVV, nor IJR, nor peers were able to outcompete it. Yet there are still a few nuances that will be addressed shortly.

Besides, in the group of value ETFs I cover, XSVM’s hybrid value/momentum approach demonstrated one of the strongest price returns over the 3-year period, delivering almost 61%, with the closest results being the actively managed Avantis US Small Cap Value ETF’s (AVUV) 60.37% and Vanguard U.S. Value Factor ETF’s (VFVA) 45.96%. Regarding the total return, it is in second place, as it trailed AVUV by a few bps.

Ticker 3Y total return
AVUV 68.59%
XSVM 68.14%
VFVA 56.08%

Data from Seeking Alpha

Phenomenal value factor exposure

With hawkish monetary policy being front and center once again, investors have a plethora of reasons to maintain sizable exposure to value stocks, as they are, in theory, less sensitive to the interest rates eating into growth premia (or, another way of saying, the increasing cost of equity).

Here, bulls might confidently say that XSVM delivers on the value front. Below are a few facts to corroborate.

Metric 7-Nov
Market Cap $1,812 million
P/S 0.9
EY 12.92%
Quant Valuation B- or higher 67%
Quant Valuation D+ or weaker 7.2%

Calculated using data from Seeking Alpha and the fund; financial data as of November 8

More specifically, XSVM’s 113-strong portfolio is not only concentrated in small caps, with a weighted-average market cap significantly below $2 billion (even though slightly more than a third of the net assets are allocated to midcaps). It also has a P/S of just 0.9x, which is not coincidental assuming 74.7% of its holdings have that ratio below 1x. The earnings yield is spectacular. Even with the impact of Ambac Financial Group (AMBC) and Community Health Systems (CYH) removed, the EY will still be solid at 11.6%.

Ticker EY
AMBC 82.8%
CYN 70.2%

Calculated using data from Seeking Alpha and the fund

Most importantly, its exposure to stocks with a B- Quant Valuation rating or higher is one of the largest among the funds I have covered to date.

Bears are retorting

Be prepared for excruciating volatility

Obviously, investors should expect wild price swings from a fund with ‘momentum’ in its name. XSVM is not an exception. And with volatility factored in, its performance is not as attractive as it seems. A standard deviation of 30.65% and the maximum drawdown of almost 41% are telling.

Moreover, XSVM can lose much more than 10% a month easily. Let me contextualize this with IVV and IJR.

Ticker Above 10% total return Below (10)%
XSVM 6 4
IVV 2 1
IJR 3 1

Calculated using data from Portfolio Visualizer

My analysis showed that over the July 2019-October 2023 period, XSVM had six months with an over 10% total return and four months when it was down by more than 10%. And even IJR cannot match it here, let alone IVV.

Besides, in December 2021, I said that its “meteoric growth will be hard to replicate.” I gave the following answer to the question about whether XSVM was “on the brink of another banner year”:

Not necessarily. I believe sterling 2021 is more of a deviation, and 2022 should be way less spectacular, as numerous headwinds from persistent inflation are clouding the outlook for the small-cap league, while tailwinds that undergirded its alpha returns earlier this year have mostly lost steam.

It seems that I was right, as after a 55.89% total return in 2021 (mostly the consequence of just two months, January with 23.37% and March with 13.44%), it dropped by 13.64% in 2022 and then advanced by a meager 41 bps in 2023. As a consequence, it significantly underperformed the S&P 500 index.

XSVM performance since coverage

Seeking Alpha

High turnover is to be tolerated

XSVM’s portfolio changes drastically over time, not because of the frequent reconstitution (there is a biannual schedule), but due to the selectiveness of the methodology. In this regard, an 86% turnover does not come as a surprise. To give a bit more color, only 40% of the fund’s current holdings were present in the portfolio as of December 10, 2021. Simply put, investors should be prepared for remarkable shifts in exposures.

Numerous EPS contraction stories

In the current iteration, XSVM has a large allocation to companies that are forecast to deliver lower earnings per share going forward, around 36%.

Fwd EPS Fwd Revenue
10.8% 4.73%

Calculated using data from Seeking Alpha and the fund

Its weighted-average forward EPS growth rate is mostly supported by just four stocks. With their impact removed, it will drop to 4.7%.

Stock Weight Sector Fwd EPS
Wabash National Corporation (WNC) 0.5% Industrials 437.94%
Apogee Enterprises (APOG) 0.6% Industrials 214.38%
NOW (DNOW) 0.9% Industrials 130.91%
CONSOL Energy (CEIX) 1.4% Energy 103.91%

Data from Seeking Alpha and the fund

Also, about a quarter of holdings have a D+ EPS Revisions grade or lower, which implies analysts have become more bearish on their profits.

Quality: expectations should not be set too high

Something that does not change over time is XSVM’s rather soft quality. In the previous note, I mentioned that “only around 41% of its portfolio is allocated to stocks with solid Profitability grades.” This figure has risen to almost 53% since then but still remains well below a comfortable level of 80%. In its defense, I should mention that the fund has an overall healthy Return on Assets of 7% and only small exposure to cash-burning companies (7%).

Final thoughts

XSVM’s unique factor approach is supposed to be an answer to the chronic underperformance of value strategies. To a certain degree, it did achieve that, but at the expense of high turnover and painful volatility. I truly like XSVM’s value profile, but due to disadvantages discussed above, there will be no rating upgrade today.

Read the full article here

News November 10, 2023 November 10, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Excelerate Energy: Nearby Best Energy-Source Cap-Gain Prospect (NYSE:EE)

The primary focus of this article is Excelerate Energy, Inc. (NYSE:EE). Investment…

Penske Is Steady, But The Road Ahead May Be Bumpy (NYSE:PAG)

Investing Thesis On Wednesday, Penske Automotive Group (NYSE:PAG) released a superficially encouraging…

Top Financial – No, Stop It, This Is Silly (NASDAQ:TOP)

TOP Financial Moves, yes, but why? TOP Financial (NASDAQ:TOP) was quite the…

You Might Also Like

News

eToro: The Disconnect (NASDAQ:ETOR) | Seeking Alpha

By News
News

Columbia Dividend Income Fund Q3 2025 Commentary (undefined:GSFTX)

By News
News

T1 Energy Stock Is A High-Risk, High-Reward Stock (NYSE:TE)

By News
News

TMC the metals company Stock: Fully Valued At Present I Think (NASDAQ:TMC)

By News
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Contact US
More Info
  • Newsletter
  • Finance
  • Investing
  • Small Business
  • Dept Management

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions

Join Community

2025 © wealthbeatnews.com. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc.

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Lost your password?